Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
US Stock MarketDetailed Quotes
SLNO Soleno Therapeutics
- 71.4500
- -0.5400-0.75%
Close Mar 31 16:00 ET
- 71.5900
- +0.1400+0.20%
Pre 06:32 ET
3.28BMarket Cap-16.31P/E (TTM)
73.9400High69.8700Low4.01MVolume71.5400Open71.9900Pre Close288.23MTurnover12.89%Turnover RatioLossP/E (Static)45.86MShares73.967852wk High13.37P/B2.22BFloat Cap36.610052wk Low--Dividend TTM31.07MShs Float742.5000Historical High--Div YieldTTM5.65%Amplitude0.8500Historical Low71.9480Avg Price1Lot Size
About Soleno Therapeutics Company
Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.
Company Profile
SymbolSLNO
Company NameSoleno Therapeutics
Listing DateNov 13, 2014
Founded1999
CEODr. Anish Bhatnagar, M.D.
MarketNASDAQ
Employees92
Fiscal Year Ends12-31
Address100 Marine Parkway,Suite 400
CityRedwood City
ProvinceCalifornia
CountryUnited States of America
Zip Code94065
Phone1-650-213-8444
Websitehttp://www.soleno.life
Company Executives
- Name
- Position
- Salary
- Dr. Anish Bhatnagar, M.D.
- President, Chief Executive Officer and Director
- 4.12M
- Meredith S. Manning
- Chief Commercial Officer
- --
- James H. Mackaness
- Chief Financial Officer and Principal Accounting Officer
- 1.21M
- Patricia C. Hirano
- Senior Vice President, Regulatory Affairs
- 1.03M
- Kristen Yen
- Senior Vice President, Clinical Operations
- --
- Dr. Michael Huang, M.D.
- Senior Vice President, Clinical Development
- --
- Dawn Carter Bir
- Director
- --
- William G. Harris
- Independent Director
- 111.87K
- Matthew Pauls, J.D.,M.B.A.
- Lead Independent Director
- 70.53K
- Dr. Birgitte Volck, M.D.,PhD
- Independent Director
- 102.87K
- Dr. Andrew Sinclair, PhD
- Independent Director
- 51.87K
Market Insights
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina
Moomoo News Global
Mar 4 23:26
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call